BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

• BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma.
• Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile.
• BioLineRx is currently testing Motixafortide in a Phase 2b trial for pancreatic cancer.

Shares of BioLineRx Ltd. (BLRX) surged 10% in pre-market trading on Tuesday, putting the stock on track to test its 50-day moving average for the first time since early March, after the company hit a significant milestone by dosing the first patient in an early-stage trial of its new cancer therapy.

BioLineRx has partnered with Hemispherian AS, a clinical-stage oncology firm, to conduct a trial testing GLIX1 in patients with Glioblastoma and other high-grade brain tumors.

Meanwhile, retail sentiment for BLRX on Stocktwits remained in the ‘neutral’ territory over the past 24 hours.

Initial Trial Results Expected In 2027

GLIX1 is a first-in-class oral therapy designed to selectively damage cancer cells by restoring TET2 activity, a tumor suppressor gene. This novel approach could provide a new treatment option for aggressive tumors such as Glioblastoma, where effective therapies remain limited, BioLineRx said.

Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile. The Phase 1 trial will enroll up to 30 patients to determine a safe dose, with initial results expected in the first half of 2027.

“We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications, where DNA damage repair is critical for cancer survival,” said Philip Serlin, CEO of BioLineRx.

What Else Is In The Pipeline?

BioLineRx is testing Motixafortide in a Phase 2b trial for pancreatic cancer, combining it with immunotherapy and standard chemotherapy. The study is progressing quickly, with an interim analysis expected later this year.

The company is also testing Motixafortide for Sickle Cell Disease (SCD) and gene therapy. A Phase 1 study showed the drug can help mobilize stem cells for gene therapy in sickle cell disease.

The stock has shed 22% of its value so far in 2026.

Read also: Why Did GLND Stock Crash 30% In Pre-Market Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.